Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence
Open accessThe DOI matches its Crossref record; 303 of the 303 references it cites were found in a registry or an index.
Abstract
Immunotherapies play critical roles in cancer treatment. However, given that only a few patients respond to immune checkpoint blockades and other immunotherapeutic strategies, more novel technologies are needed to decipher the complicated interplay between tumor cells and the components of the tumor immune microenvironment (TIME). Tumor immunomics refers to the integrated study of the TIME using immunogenomics, immunoproteomics, immune-bioinformatics, and other multi-omics data reflecting the immune states of tumors, which has relied on the rapid development of next-generation sequencing. High-throughput genomic and transcriptomic data may be utilized for calculating the abundance of immune cells and predicting tumor antigens, referring to immunogenomics. However, as bulk sequencing represents the average characteristics of a heterogeneous cell population, it fails to distinguish distinct cell subtypes. Single-cell-based technologies enable better dissection of the TIME through precise immune cell subpopulation and spatial architecture investigations. In addition, radiomics and digital pathology-based deep learning models largely contribute to research on cancer immunity. These artificial intelligence technologies have performed well in predicting response to immunotherapy, with profound significance in cancer therapy. In this review, we briefly summarize conventional and state-of-the-art technologies in the field of immunogenomics, single-cell and artificial intelligence, and present prospects for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Single‐cell‐based technologies have enabled a better dissection of the TME through precise monitoring of cell sub‐populations and spatial architecture, thus revealing the heterogeneous and complex nature of the TME [10, 12].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 1×
“58,59 60 – 62 However, regarding false positivity or false negativity, none of these tools is satisfactory in all aspects.”
BackgroundPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“50,51 55 – 57 Regarding liquid tumor analysis, Strelka2 introduces a normal sample contamination model to improve the variant calling accuracy and functions fairly well in the computing cost.”
BackgroundA global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0201-4 · Cited by 15,022 · cited 1×
“84,85 However, considering the complexity of the HLA types, we still expect independent benchmarking studies and more tools to be presented.”
BackgroundThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224 · cited 1×
“30 QuanTIseq is designed speci-fi cally for RNA-seq data, and the analysis pipeline comprises raw RNA-seq data preprocessing, gene expression quanti fi cation, and constrained least squares regression-based deconvolution.”
MethodSelf-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“As a target of ICB, the PD-L1 expression level detected by IHC was the fi rst discovered prediction biomarker, 217 but several clinical trials have revealed moderate ef fi cacy of ICB in patients with high PD-L1 expression.”
BackgroundInferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · cited 1×
“27 The ESTIMATE score can differentiate the tumor and stomal components but cannot distinguish speci fi c immune cell types. xCell is another ssGSEA-based method that obtains gene sets to characterize distinct cell types from multiple RNA-seq and microarray-based data sources, increasing the…”
MethodRadiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421 · cited 1×
“185 To the best of our knowledge, radiomics technology applied to tumor immunity is mainly used to identify biomarkers re fl ecting immune in fi ltration and predict the therapeutic response of ICB-treated patients (Fig.”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Spatial reconstruction of single-cell gene expression data
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., & Regev, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3192 · Cited by 7,055 · cited 1×
“175,176 Andersson et al. 177 also developed a model-based probabilistic method that performs guided deconvolution of mixed expression pro fi les to integrate scRNA-seq and spatial transcriptomics data and then spatially map cell types.”
MethodOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“4,5 12 Nevertheless, in the face of therapeutic resistance and adverse effects, among others, their applications are hindered by the incomplete understanding of tumor immunity.”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 2×
“20,21 There are two main categories for the compositions of the TIME, i.e., immune cells and secreted factors, such as cytokines, chemokines, and growth factors.”
BackgroundMethodAxicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 1×
“38 In addition, these algorithms were applied to compare the TIME composition of two or more groups of patients with distinct pathological features, therapeutic strategies, and treatment responses.”
MethodSelf-citationElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“226 Nonetheless, a considerable proportion of TILs are only a bystander without cytolytic effects on tumor cells.”
BackgroundSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Tirosh et al. 141 unraveled the ecosystem of metastatic melanoma by scRNA-seq to provide insight with implications for both targeted and immune therapies.”
BackgroundVarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,905 · cited 1×
“50,51 55 – 57 Regarding liquid tumor analysis, Strelka2 introduces a normal sample contamination model to improve the variant calling accuracy and functions fairly well in the computing cost.”
BackgroundRajkomar, A., Dean, J., & Kohane, I. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1814259 · Cited by 4,579
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0114-2 · Cited by 4,478 · cited 1×
“34 These immunogenomics technologies are widely used to elaborate the global immune in fi ltration characteristics of speci fi c cancer types.”
MethodxCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397 · cited 1×
“28 MCP-counter generates an abundance score for each TIME cell population (including not only immune cells but also endothelial cells and fi broblasts) in every single sample based on the geometric mean of marker gene expression levels.”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · cited 3×
“22,119 Therefore, characterizing the TIME and determining the cellular components could be highly bene fi cial for tumor immunity studies.”
BackgroundMethodTumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · cited 1×
“221 On the other hand, immune cell in fi ltrations, particularly TILs, play a pivotal role in the immune response.”
BackgroundCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“4,5 12 Nevertheless, in the face of therapeutic resistance and adverse effects, among others, their applications are hindered by the incomplete understanding of tumor immunity.”
BackgroundVisualization and analysis of gene expression in tissue sections by spatial transcriptomics
Ståhl, P. L., Salmén, F., Vickovic, S., Lundmark, A., Navarro, J. F., Magnusson, J., Giacomello, S., Asp, M., Westholm, J. O., Huss, M., et al. (2016) · Science · doi:10.1126/science.aaf2403 · Cited by 3,834
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685 · cited 1×
“29 For the sake of accuracy, a common characteristic of GSEA-based methods is the need for a speci fi c gene set for each immunocyte subpopulation of interest.”
MethodMicroenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 1×
“2,3 And accordingly, promoting the transition from a pro-tumor to an anti-tumor effect to maximize the ef fi cacy of anti-tumor immunity is a main goal of immunotherapy.”
BackgroundA Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545 · cited 1×
“257,258 269 Immunogenomics approaches have been widely applied in vaccine development in clinical research.”
BackgroundCar t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · cited 1×
“242 248 Currently, neoantigen-speci fi c TCR-engineered T cells have not been applied clinically at bedside.”
BackgroundCell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq
Zeisel, A., Muñoz-Manchado, A. B., Codeluppi, S., Lönnerberg, P., La Manno, G., Juréus, A., Marques, S., Munguba, H., He, L., Betsholtz, C., et al. (2015) · Science · doi:10.1126/science.aaa1934 · Cited by 3,124
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · cited 1×
“212 Consequently, blockades of such checkpoints reinforce anti-tumor immunity and yield durable therapy responses in cancer patients.”
BackgroundAn immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · cited 1×
“262 Similarly, neoantigen vaccines have shown ef fi cacy in phase Ib clinical trials of glioblastoma.”
BackgroundCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Artificial intelligence in healthcare
Yu, K.-H., Beam, A. L., & Kohane, I. S. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0305-z · Cited by 2,817
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731 · cited 1×
“Furthermore, Helmink et al. 235 leveraged CyTOF and single-cell sequencing to reveal a distinctive B cell functional status and tertiary lymphoid structure localization in a melanoma neoadjuvant ICB clinical trial cohort.”
BackgroundAnderson, N. M., & Simon, M. C. (2020) · Current Biology · doi:10.1016/j.cub.2020.06.081 · Cited by 2,718
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Li, B., Severson, E., Pignon, J.-C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J. C., Rodig, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,451
Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution
Rodriques, S. G., Stickels, R. R., Goeva, A., Martin, C. A., Murray, E., Vanderburg, C. R., Welch, J., Chen, L. M., Chen, F., & Macosko, E. Z. (2019) · Science · doi:10.1126/science.aaw1219 · Cited by 2,424
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075 · cited 2×
“224,225 Substantial studies have proven that the intensity of TILs strongly correlates with the ICB response and clinical outcomes.”
BackgroundAbsolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044 · cited 1×
“88,89 Despite substantial research on MHC-I and tumor immunotherapy, recent studies have shown that tumor-speci fi c MHC-II molecules are also associated with favorable outcomes in patients with cancer.”
BackgroundSingle-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
Giesen, C., Wang, H. A. O., Schapiro, D., Zivanovic, N., Jacobs, A., Hattendorf, B., Schüffler, P. J., Grolimund, D., Buhmann, J. M., Brandt, S., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2869 · Cited by 1,951 · cited 5×
“156,162 Notably, the onset of multiplexed ion beam imaging by time-of-fl ight (MIBI-TOF) had an impact on this fi eld.”
BackgroundMethodInfluentialA universal SNP and small-indel variant caller using deep neural networks
Poplin, R., Chang, P.-C., Alexander, D., Schwartz, S., Colthurst, T., Ku, A., Newburger, D., Dijamco, J., Nguyen, N., Afshar, P. T., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4235 · Cited by 1,840 · cited 1×
“182 Regarding HLA typing, Bulik et al. 183 generated a large integrated dataset including HLA types and HLA peptides from various types of cancer tissues and published data that could be used to train the full mass spectrometry deep learning model EDGE, which has been validated in non-small-cell…”
MethodMacrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · cited 1×
“15 – 17 Encompassing all structures in the organ, such as immune in fi ltration, vascular vessels, the extracellular matrix, etc. the tumor surrounding, which is also called the tumor micro-environment (TME), has been one of the hottest research topics in oncology.”
BackgroundSingle-cell RNA sequencing to explore immune cell heterogeneity
Papalexi, E., & Satija, R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.76 · Cited by 1,806
Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types
Jaitin, D. A., Kenigsberg, E., Keren-Shaul, H., Elefant, N., Paul, F., Zaretsky, I., Mildner, A., Cohen, N., Jung, S., Tanay, A., et al. (2014) · Science · doi:10.1126/science.1247651 · Cited by 1,795 · cited 1×
“139,140 Subsequently, research applying scRNA-seq to depict the TIME began worldwide.”
MethodCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718 · cited 1×
“251 Resulting from the dif fi culty in isolating TILs from tumor sites, peripheral blood neoantigen-recognizing T cells were isolated and proved to be identical to TILs in the immunological process.”
MethodSiddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
Guo, X., Zhang, Y., Zheng, L., Zheng, C., Song, J., Zhang, Q., Kang, B., Liu, Z., Jin, L., Xing, R., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0045-3 · Cited by 1,651
Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,635 · cited 1×
“58,59 60 – 62 However, regarding false positivity or false negativity, none of these tools is satisfactory in all aspects.”
BackgroundRobbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Strelka2: fast and accurate calling of germline and somatic variants
Kim, S., Scheffler, K., Halpern, A. L., Bekritsky, M. A., Noh, E., Källberg, M., Chen, X., Kim, Y., Beyter, D., Krusche, P., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0051-x · Cited by 1,632
Finotello, F., Mayer, C., Plattner, C., Laschober, G., Rieder, D., Hackl, H., Krogsdam, A., Loncova, Z., Posch, W., Wilflingseder, D., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0638-6 · Cited by 1,542
Clonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534 · cited 1×
“It 230 – 233 CyTOF was performed to compare the TIME of pre-and post-ICB-administered advanced melanoma patients.”
MethodSingle-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
Zhang, L., Li, Z., Skrzypczynska, K. M., Fang, Q., Zhang, W., O’Brien, S. A., He, Y., Wang, L., Zhang, Q., Kim, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.048 · Cited by 1,526
Deep profiling of mouse splenic architecture with CODEX multiplexed imaging
Goltsev, Y., Samusik, N., Kennedy-Darling, J., Bhate, S., Hale, M., Vazquez, G., Black, S., & Nolan, G. P. (2018) · Cell · doi:10.1016/j.cell.2018.07.010 · Cited by 1,501 · cited 2×
“With the help of CODEX, Goltsev et al. 151 observed many previously uncharacterized splenic cell-interaction dynamics in fresh-frozen spleen tissues from animals with systemic autoimmune disease, which is promising for enabling the systemic characterization of tissue architecture.”
MethodComparative Analysis of Single-Cell RNA Sequencing Methods
Ziegenhain, C., Vieth, B., Parekh, S., Reinius, B., Guillaumet-Adkins, A., Smets, M., Leonhardt, H., Heyn, H., Hellmann, I., & Enard, W. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.023 · Cited by 1,494
The Technology and Biology of Single-Cell RNA Sequencing
Kolodziejczyk, A. A., Kim, J. K., Svensson, V., Marioni, J. C., & Teichmann, S. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.005 · Cited by 1,487 · cited 1×
“Here, we mainly discuss several technologies applied to the tumor immune cell repertoire and TIME spatial architecture 20,116 – 118 (Table 3).”
MethodEngineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Jurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,470
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470 · cited 1×
“2,3 And accordingly, promoting the transition from a pro-tumor to an anti-tumor effect to maximize the ef fi cacy of anti-tumor immunity is a main goal of immunotherapy.”
BackgroundNeoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · cited 1×
“267 Similar to ACT, the crucial parameter of tumor vaccine development is ideal neoantigen identi fi cation.”
BackgroundSimultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E., & Gfeller, D. (2017) · eLife · doi:10.7554/elife.26476 · Cited by 1,384
Wilm, A., Aw, P. P. K., Bertrand, D., Yeo, G. H. T., Ong, S. H., Wong, C. H., Khor, C. C., Petric, R., Hibberd, M. L., & Nagarajan, N. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks918 · Cited by 1,372
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370 · cited 1×
“227 To discover more ideal therapeutic and prognostic biomarkers, single-cell sequencing was used to identify more immune cell subpopulations.”
MethodT-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338 · cited 1×
“23,24 However, available studies have con fi rmed that given the complex interactions with tumor cells, the speci fi c role of immune cells could dynamically change and even become the exact opposite.”
BackgroundA dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Chen, Y.-T., Scanlan, M. J., Sahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., & Old, L. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1914 · Cited by 1,247 · cited 1×
“257,258 269 Immunogenomics approaches have been widely applied in vaccine development in clinical research.”
BackgroundSun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236 · cited 1×
“191 This biomarker was more effective than the lesion volume in predicting the immunotherapy response and overall survival.”
BackgroundMass Cytometry: Single Cells, Many Features
Spitzer, M. H., & Nolan, G. P. (2016) · Cell · doi:10.1016/j.cell.2016.04.019 · Cited by 1,199 · cited 3×
“127 We believe that we can only fi nd “ THE KNOWN UNKNOWN ” via these technologies.”
BackgroundMethodTumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183 · cited 1×
“164 In 2019, a purpose-built mass spectrometer for MIBI analysis was also designed to further promote the application of MIBI-TOF.”
MethodSingle-cell sequencing-based technologies will revolutionize whole-organism science
Shapiro, E., Biezuner, T., & Linnarsson, S. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3542 · Cited by 1,177
Computational and analytical challenges in single-cell transcriptomics
Stegle, O., Teichmann, S. A., & Marioni, J. C. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3833 · Cited by 1,170
High-definition spatial transcriptomics for in situ tissue profiling
Vickovic, S., Eraslan, G., Salmén, F., Klughammer, J., Stenbeck, L., Schapiro, D., Äijö, T., Bonneau, R., Bergenstråhle, L., Navarro, J. F., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0548-y · Cited by 1,150
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Method of the Year: spatially resolved transcriptomics
Marx, V. (2021) · Nature Methods · doi:10.1038/s41592-020-01033-y · Cited by 1,132
Multiplexed ion beam imaging of human breast tumors
Angelo, M., Bendall, S. C., Finck, R., Hale, M. B., Hitzman, C., Borowsky, A. D., Levenson, R. M., Lowe, J. B., Liu, S. D., Zhao, S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3488 · Cited by 1,108 · cited 2×
“Consistent with the high-dimensional imaging technology IMC and MIBI-TOF, 156,163,165 digital pathology could be a promising approach for investigating the TIME structure and the relationship between cancer biology and therapy.”
MethodGene Regulation at the Single-Cell Level
Rosenfeld, N., Young, J. W., Alon, U., Swain, P. S., & Elowitz, M. B. (2005) · Science · doi:10.1126/science.1106914 · Cited by 1,104
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Kim, C., Gao, R., Sei, E., Brandt, R., Hartman, J., Hatschek, T., Crosetto, N., Foukakis, T., & Navin, N. E. (2018) · Cell · doi:10.1016/j.cell.2018.03.041 · Cited by 1,104 · cited 1×
“142 Thus, the prospects of single-cell sequencing technologies are promising and deserve further investigation considering their scienti fi c merit and clinical signi fi cance.”
BackgroundKather, J. N., Krisam, J., Charoentong, P., Luedde, T., Herpel, E., Weis, C.-A., Gaiser, T., Marx, A., Valous, N. A., Ferber, D., et al. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002730 · Cited by 1,082 · cited 1×
“201 Furthermore, predictive models that incorporate the immune cell composition and spatial organization correlate with cancer prognosis, which several groups have proven in colorectal cancer, HCC, and melanoma 202 – 205 (Fig.”
BackgroundLi, H., Courtois, E. T., Sengupta, D., Tan, Y., Chen, K. H., Goh, J. J. L., Kong, S. L., Chua, C., Hon, L. K., Tan, W. S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3818 · Cited by 1,080
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Schürch, C. M., Bhate, S. S., Barlow, G. L., Phillips, D. J., Noti, L., Zlobec, I., Chu, P., Black, S., Demeter, J., McIlwain, D. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.005 · Cited by 1,064
WGS500 Consortium, Rimmer, A., Phan, H., Mathieson, I., Iqbal, Z., Twigg, S. R. F., Wilkie, A. O. M., McVean, G., & Lunter, G. (2014) · Nature Genetics · doi:10.1038/ng.3036 · Cited by 1,057
Saltz, J., Gupta, R., Hou, L., Kurc, T., Singh, P., Nguyen, V., Samaras, D., Shroyer, K. R., Zhao, T., Batiste, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.086 · Cited by 1,027
Self-citationParkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020 · cited 1×
“242 248 Currently, neoantigen-speci fi c TCR-engineered T cells have not been applied clinically at bedside.”
BackgroundSeventeen-colour flow cytometry: unravelling the immune system
Perfetto, S. P., Chattopadhyay, P. K., & Roederer, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1416 · Cited by 1,019
Wieczorek, M., Abualrous, E. T., Sticht, J., Álvaro-Benito, M., Stolzenberg, S., Noé, F., & Freund, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00292 · Cited by 1,005 · cited 1×
“86,87 Human MHC molecules are divided into the following three subtypes: Class I, Class II, and Class III.”
BackgroundAn Immune Atlas of Clear Cell Renal Cell Carcinoma
Chevrier, S., Levine, J. H., Zanotelli, V. R. T., Silina, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,004 · cited 1×
“128,129 Chevrier et al. 130 applied mass cytometry to successfully depict an in-depth atlas of the TIME in clear renal cell carcinoma and correlated immune compositions with clinical features, which has great clinical signi fi cance and could guide follow-up studies.”
BackgroundLiver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Yu, J., Green, M. D., Li, S., Sun, Y., Journey, S. N., Choi, J. E., Rizvi, S. M., Qin, A., Waninger, J. J., Lang, X., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1131-x · Cited by 1,001
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15081 · Cited by 992
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992 · cited 1×
“111 In addition to intra-tumoral heterogeneity (ITH) and the dramatic diversity of immune cells, numerous signi fi cant biological phenomena may be obscured by bulk sequencing in the exploration of tumor immunity.”
BackgroundAccounting for technical noise in single-cell RNA-seq experiments
Brennecke, P., Anders, S., Kim, J. K., Kołodziejczyk, A. A., Zhang, X., Proserpio, V., Baying, B., Benes, V., Teichmann, S. A., Marioni, J. C., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2645 · Cited by 979
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
Lai, Z., Markovets, A., Ahdesmaki, M., Chapman, B., Hofmann, O., McEwen, R., Johnson, J., Dougherty, B., Barrett, J. C., & Dry, J. R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw227 · Cited by 970 · cited 1×
“58,59 60 – 62 However, regarding false positivity or false negativity, none of these tools is satisfactory in all aspects.”
BackgroundHigh-Spatial-Resolution Multi-Omics Sequencing via Deterministic Barcoding in Tissue
Liu, Y., Yang, M., Deng, Y., Su, G., Enninful, A., Guo, C. C., Tebaldi, T., Zhang, D., Kim, D., Bai, Z., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.026 · Cited by 966 · cited 1×
“172 Notably, ZipSeq can label live cells in intact tissues with unique illumination and photocaged oligonucleotide “ zipcodes ” and then lyse tissues into individual cells for RNA-seq to broaden the scope of research.”
BackgroundSelf-citationCOLEY, W. B. (1991) · PubMed · Cited by 965
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938
Origin and evolution of the adaptive immune system: genetic events and selective pressures
Flajnik, M. F., & Kasahara, M. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2703 · Cited by 931 · cited 1×
“88,89 Despite substantial research on MHC-I and tumor immunotherapy, recent studies have shown that tumor-speci fi c MHC-II molecules are also associated with favorable outcomes in patients with cancer.”
BackgroundFlow cytometry: basic principles and applications
Adan, A., Alizada, G., Kiraz, Y., Baran, Y., & Nalbant, A. (2017) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1128876 · Cited by 920 · cited 1×
“120 Flow cytometry has emerged as a core tool in medical research, particularly regarding tumor immune cells.”
BackgroundBulk tissue cell type deconvolution with multi-subject single-cell expression reference
Wang, X., Park, J., Susztak, K., Zhang, N. R., & Li, M. (2019) · Nature Communications · doi:10.1038/s41467-018-08023-x · Cited by 913 · cited 1×
“33 However, the sensitivity and speci fi city of the newly developed algorithms mentioned above require more validation.”
MethodThe single-cell pathology landscape of breast cancer
Jackson, H. W., Fischer, J. R., Zanotelli, V. R. T., Ali, H. R., Mechera, R., Soysal, S. D., Moch, H., Muenst, S., Varga, Z., Weber, W. P., et al. (2020) · Nature · doi:10.1038/s41586-019-1876-x · Cited by 900
MALDI imaging mass spectrometry: molecular snapshots of biochemical systems
Cornett, D. S., Reyzer, M. L., Chaurand, P., & Caprioli, R. M. (2007) · Nature Methods · doi:10.1038/nmeth1094 · Cited by 886
ProPred: prediction of HLA-DR binding sites
Singh, H., & Raghava, G. P. S. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.12.1236 · Cited by 841
Pathogenic Germline Variants in 10,389 Adult Cancers
Huang, K.-L., Mashl, R. J., Wu, Y., Ritter, D. I., Wang, J., Oh, C., Paczkowska, M., Reynolds, S., Wyczalkowski, M. A., Oak, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.039 · Cited by 833 · cited 1×
“66,67 Furthermore, it is advisable to select more than two tools to predict abnormal proteins in practice.”
BackgroundGros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829 · cited 1×
“252 Thus, WES along with neoantigen T cell isolation has become a promising approach for promoting noninvasive cancer therapeutic strategies.”
BackgroundProteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
Present yourself! by MHC class I and MHC class II molecules
Rock, K. L., Reits, E., & Neefjes, J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.010 · Cited by 814 · cited 1×
“86,87 Human MHC molecules are divided into the following three subtypes: Class I, Class II, and Class III.”
BackgroundLundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O., & Nielsen, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn202 · Cited by 808 · cited 1×
“50 93 Moreover, even without ANN training, the PSSM-based software called PSSMHCpan could accurately and ef fi ciently predict the pMHC-I binding af fi nity.”
MethodRobbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
Improved methods for predicting peptide binding affinity to MHC class II molecules
Jensen, K. K., Andreatta, M., Marcatili, P., Buus, S., Greenbaum, J. A., Yan, Z., Sette, A., Peters, B., & Nielsen, M. (2018) · Immunology · doi:10.1111/imm.12889 · Cited by 794
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783 · cited 1×
“224,225 Substantial studies have proven that the intensity of TILs strongly correlates with the ICB response and clinical outcomes.”
BackgroundTumor microenvironment: Sanctuary of the devil
Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 779 · cited 1×
“15 – 17 Encompassing all structures in the organ, such as immune in fi ltration, vascular vessels, the extracellular matrix, etc. the tumor surrounding, which is also called the tumor micro-environment (TME), has been one of the hottest research topics in oncology.”
BackgroundZacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y.-C., Zheng, Z., Pasetto, A., Langhan, M., Shelton, T., Prickett, T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 773
OptiType: precision HLA typing from next-generation sequencing data
Szolek, A., Schubert, B., Mohr, C., Sturm, M., Feldhahn, M., & Kohlbacher, O. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu548 · Cited by 769
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751 · cited 2×
“22,23 Normally, T cells, B cells, NK cells, and macrophages help inhibit tumor growth, while MDSCs and regulatory T cells (Tregs) tend to suppress anti-tumor immunity.”
BackgroundOtt, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735 · cited 1×
“Krieg et al. 234 identi fi ed CD14 + CD16 − HLA-DRhi monocytes for the prediction of the response to anti-PD-1 therapy.”
BackgroundIntratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.017 · Cited by 734
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue
Gerdes, M. J., Sevinsky, C. J., Sood, A., Adak, S., Bello, M. O., Bordwell, A., Can, A., Corwin, A., Dinn, S., Filkins, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300136110 · Cited by 724 · cited 2×
“154 However, the characteristic feature of these technologies also results in a disadvantage, as follows: repeated elution and imaging could change the antigenicity of the target specimen and may cost too much time and money.”
BackgroundFriebel, E., Kapolou, K., Unger, S., Núñez, N. G., Utz, S., Rushing, E. J., Regli, L., Weller, M., Greter, M., Tugues, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.055 · Cited by 685 · cited 1×
“131 Although mass cytometry theoretically allows us to detect at most 100 parameters per cell, the processing speed and throughput are limited by ion fl ight.”
BackgroundNotch Signaling in the Tumor Microenvironment
Meurette, O., & Mehlen, P. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.009 · Cited by 678 · cited 1×
“18,19 With the development of tumor immunity, the immune context of the TME, i.e., TIME, has been proven to play a decisive role in carcinogenesis, tumor progression, metastasis, recurrence, and potential therapeutic targets making it being the focus of our review.”
BackgroundTan, W. C. C., Nerurkar, S. N., Cai, H. Y., Ng, H. H. M., Wu, D., Wee, Y. T. F., Lim, J. C. T., Yeong, J., & Lim, T. K. H. (2020) · Cancer Communications · doi:10.1002/cac2.12023 · Cited by 678 · cited 1×
“149,150 Multiplex immunohistochemistry/immuno fl uores-cence (mIHC/IF) enables the simultaneous detection of multiple markers on a single slice, improving our understanding of the TIME spatial architecture.”
BackgroundComprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Shukla, S. A., Rooney, M. S., Rajasagi, M., Tiao, G., Dixon, P. M., Lawrence, M. S., Stevens, J., Lane, W. J., Dellagatta, J. L., Steelman, S., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3344 · Cited by 675 · cited 1×
“82 Graph-guided genotyping tools used to perform highly classical HLA typing, such as Kourami and HISAT2, provide a new perspective to improve the ef fi cacy of typing.”
SomaticSniper: identification of somatic point mutations in whole genome sequencing data
Larson, D. E., Harris, C. C., Chen, K., Koboldt, D. C., Abbott, T. E., Dooling, D. J., Ley, T. J., Mardis, E. R., Wilson, R. K., & Ding, L. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr665 · Cited by 661
Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens
Jia, X., Han, B., Onengut-Gumuscu, S., Chen, W.-M., Concannon, P. J., Rich, S. S., Raychaudhuri, S., & de Bakker, P. I. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064683 · Cited by 645
A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome
Hong, W., Yang, J., Bi, Z., He, C., Lei, H., Yu, W., Yang, Y., Fan, C., Lu, S., Peng, X., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00451-w · Cited by 627
Single-cell RNA sequencing for the study of development, physiology and disease
Potter, S. S. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0021-7 · Cited by 622 · cited 1×
“Here, we mainly discuss several technologies applied to the tumor immune cell repertoire and TIME spatial architecture 20,116 – 118 (Table 3).”
MethodTumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 613
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607 · cited 1×
“20,21 There are two main categories for the compositions of the TIME, i.e., immune cells and secreted factors, such as cytokines, chemokines, and growth factors.”
BackgroundPredicting response to cancer immunotherapy using noninvasive radiomic biomarkers
Trebeschi, S., Drago, S. G., Birkbak, N. J., Kurilova, I., Cǎlin, A. M., Delli Pizzi, A., Lalezari, F., Lambregts, D. M. J., Rohaan, M. W., Parmar, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz108 · Cited by 566 · cited 1×
“192 During ICB administration, some atypical responses have been reported.”
BackgroundSunshine, J., & Taube, J. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.011 · Cited by 560
Moutaftsi, M., Peters, B., Pasquetto, V., Tscharke, D. C., Sidney, J., Bui, H.-H., Grey, H., & Sette, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1215 · Cited by 557 · cited 1×
“99,100 105 As frequent updates, NetMHCIIpan may be the priority for researchers depending on its competitive performance.”
BackgroundDeconstructing the Peptide-MHC Specificity of T Cell Recognition
Birnbaum, M. E., Mendoza, J. L., Sethi, D. K., Dong, S., Glanville, J., Dobbins, J., Özkan, E., Davis, M. M., Wucherpfennig, K. W., & Garcia, K. C. (2014) · Cell · doi:10.1016/j.cell.2014.03.047 · Cited by 556
Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.015 · Cited by 538 · cited 1×
“In a recent study, Wells et al. 270 compiled all neoantigen prediction and selection methods and provided a brand-new candidate determination pipeline incorporating 14 immunogenic features of MHC presentation and T cell recognition.”
BackgroundHu, Z., Leet, D. E., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A. M., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01206-4 · Cited by 538
Design and Analysis of Single-Cell Sequencing Experiments
Grün, D., & van Oudenaarden, A. (2015) · Cell · doi:10.1016/j.cell.2015.10.039 · Cited by 536
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3200 · Cited by 490 · cited 1×
“90 MHC IIIs are not markers on the cell surface and are not discussed here.”
BackgroundCancer and the Immune System: The History and Background of Immunotherapy
Abbott, M., & Ustoyev, Y. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.002 · Cited by 489
Analyzing proteome topology and function by automated multidimensional fluorescence microscopy
Schubert, W., Bonnekoh, B., Pommer, A. J., Philipsen, L., Böckelmann, R., Malykh, Y., Gollnick, H., Friedenberger, M., Bode, M., & Dress, A. W. M. (2006) · Nature Biotechnology · doi:10.1038/nbt1250 · Cited by 479
Computational flow cytometry: helping to make sense of high-dimensional immunology data
Saeys, Y., Van Gassen, S., & Lambrecht, B. N. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.56 · Cited by 467 · cited 3×
“122 In addition, regarding measuring certain low-expressed molecular features, CyTOF may be inappropriate because of its low sensitivity.”
BackgroundMethodChen, Y.-P., Yin, J.-H., Li, W.-F., Li, H.-J., Chen, D.-P., Zhang, C.-J., Lv, J.-W., Wang, Y.-Q., Li, X.-M., Li, J.-Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0374-x · Cited by 463
ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer
Jiang, Y., Zhang, Q., Hu, Y., Li, T., Yu, J., Zhao, L., Ye, G., Deng, H., Mou, T., Cai, S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002116 · Cited by 458 · cited 1×
“187,188 A tumor mutational burden radiomics biomarker (TMBRB) was also developed and outperformed the current clinical models in dividing NSCLC patients into high and low tumor mutation burden (TMB) patients who have different clinical outcomes.”
MethodSelf-citationSingle-cell and spatial transcriptomics enables probabilistic inference of cell type topography
Andersson, A., Bergenstråhle, J., Asp, M., Bergenstråhle, L., Jurek, A., Fernández Navarro, J., & Lundeberg, J. (2020) · Communications Biology · doi:10.1038/s42003-020-01247-y · Cited by 457 · cited 1×
“175,176 Andersson et al. 177 also developed a model-based probabilistic method that performs guided deconvolution of mixed expression pro fi les to integrate scRNA-seq and spatial transcriptomics data and then spatially map cell types.”
MethodTechnologies for Single-Cell Isolation
Gross, A., Schoendube, J., Zimmermann, S., Steeb, M., Zengerle, R., & Koltay, P. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160816897 · Cited by 445 · cited 1×
“135 138 No longer limited by predetermined targets as fl ow cytometry, an individual cell can be sequenced using the standard NGS protocol to obtain unbiased multi-omics pro fi ling that can be used to identify “ THE UNKNOWN UNKNOWN ” .”
MethodReynisson, B., Barra, C., Kaabinejadian, S., Hildebrand, W. H., Peters, B., & Nielsen, M. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00874 · Cited by 445
O'Rawe, J., Jiang, T., Sun, G., Wu, Y., Wang, W., Hu, J., Bodily, P., Tian, L., Hakonarson, H., Johnson, W. E., et al. (2013) · Genome Medicine · doi:10.1186/gm432 · Cited by 442 · cited 1×
“63,64 How to optimize the present tools and design a versatile and ef fi cient variant caller to better discriminate true variants from sequencing errors is worthy of further research.”
BackgroundMIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure
Keren, L., Bosse, M., Thompson, S., Risom, T., Vijayaragavan, K., McCaffrey, E., Marquez, D., Angoshtari, R., Greenwald, N. F., Fienberg, H., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax5851 · Cited by 431 · cited 2×
“Consistent with the high-dimensional imaging technology IMC and MIBI-TOF, 156,163,165 digital pathology could be a promising approach for investigating the TIME structure and the relationship between cancer biology and therapy.”
BackgroundMethodColey, W. B. (1910) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591571000301601 · Cited by 423 · cited 1×
“255,256 Subsequently, the discovery of TAA paved the way for further investigations of tumor-speci fi c vaccine therapeutics.”
BackgroundAn Introduction to the Performance of Immunohistochemistry
Magaki, S., Hojat, S. A., Wei, B., So, A., & Yong, W. H. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8935-5_25 · Cited by 416 · cited 1×
“149,150 Multiplex immunohistochemistry/immuno fl uores-cence (mIHC/IF) enables the simultaneous detection of multiple markers on a single slice, improving our understanding of the TIME spatial architecture.”
BackgroundMHCflurry: Open-Source Class I MHC Binding Affinity Prediction
O'Donnell, T. J., Rubinsteyn, A., Bonsack, M., Riemer, A. B., Laserson, U., & Hammerbacher, J. (2018) · Cell Systems · doi:10.1016/j.cels.2018.05.014 · Cited by 409
Quantifying tumor-infiltrating immune cells from transcriptomics data
Finotello, F., & Trajanoski, Z. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2150-z · Cited by 407 · cited 2×
“26 CIBERSORT, which is among the most popular algorithms based on deconvolution, utilizes linear support vector regression and a gene expression signature matrix to characterize immune in fi ltrating components.”
MethodSharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I., Cohen, I. J., Maeda, M., Shindo, M., Senbabaoglu, Y., Watson, M. J., Leftin, A., Maniyar, R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 393 · cited 1×
“25 In summary, innumerable immune cell types and even different functional states of speci fi c immune cell types may produce the opposite effect on anti-tumor immunity (Fig.”
BackgroundGrasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.005 · Cited by 390 · cited 1×
“For example, Grasso et al. 272 showed that an increase in T cell in fi ltration and downstream IFN-γ signaling drive clinical responses by analyzing the CheckMate 038 study using technologies, such as NGS and immune cell quantitation, representing the regeneration of immunogenomics in the NGS era.”
MethodTumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 365
Huang, C., Chen, L., Savage, S. R., Eguez, R. V., Dou, Y., Li, Y., da Veiga Leprevost, F., Jaehnig, E. J., Lei, J. T., Wen, B., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.007 · Cited by 360 · cited 1×
“37 Remarkably, an immune landscape was interpreted with 10000 tumors of 33 cancer types compiled in TCGA.”
BackgroundPan-cancer deconvolution of tumour composition using DNA methylation
Chakravarthy, A., Furness, A., Joshi, K., Ghorani, E., Ford, K., Ward, M. J., King, E. V., Lechner, M., Marafioti, T., Quezada, S. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05570-1 · Cited by 327 · cited 1×
“41 By adopting an LTS regression as described above using the FARDEEP algorithm, MethylResolver fabricates a methylation signature compendium of the leukocyte population and accomplishes relative quanti fi cation of immune in fi ltrates and evaluation of tumor purity.”
MethodT cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323 · cited 1×
“4,5 12 Nevertheless, in the face of therapeutic resistance and adverse effects, among others, their applications are hindered by the incomplete understanding of tumor immunity.”
BackgroundSpatial transcriptomics coming of age
Burgess, D. J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0129-z · Cited by 320 · cited 1×
“171 Furthermore, not con fi ned to transcriptomics data, a recent innovation involving a micro fl uidic-based method, deterministic barcoding in tissue for spatial omics sequencing (DBiT-seq), enables the realization of high-spatial-resolution multi-omics sequencing in FFPE slides, revolutionizing a…”
MethodMak, S. S. T., Gopalakrishnan, S., Carøe, C., Geng, C., Liu, S., Sinding, M.-H. S., Kuderna, L. F. K., Zhang, W., Fu, S., Vieira, F. G., et al. (2017) · GigaScience · doi:10.1093/gigascience/gix049 · Cited by 317
Predicting HLA class II antigen presentation through integrated deep learning
Chen, B., Khodadoust, M. S., Olsson, N., Wagar, L. E., Fast, E., Liu, C. L., Muftuoglu, Y., Sworder, B. J., Diehn, M., Levy, R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0280-2 · Cited by 314 · cited 1×
“184 Racle et al. 103 developed a motif deconvolution algorithm, i.e., Modec, to train the deep learning MHC-II peptide predictor MixMHC2pred.”
MethodSingle-cell metabolic profiling of human cytotoxic T cells
Hartmann, F. J., Mrdjen, D., McCaffrey, E., Glass, D. R., Greenwald, N. F., Bharadwaj, A., Khair, Z., Verberk, S. G. S., Baranski, A., Baskar, R., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0651-8 · Cited by 308 · cited 1×
“166 In addition, MIBI-TOF and IMC can both be applied to FFPE tissue sections to perform a retrospective analysis of patient cohorts whose outcome is known.”
BackgroundDeep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 307 · cited 2×
“182 Regarding HLA typing, Bulik et al. 183 generated a large integrated dataset including HLA types and HLA peptides from various types of cancer tissues and published data that could be used to train the full mass spectrometry deep learning model EDGE, which has been validated in non-small-cell lung cancer (NSCLC) pa…”
MethodChang, Q., Ornatsky, O. I., Siddiqui, I., Loboda, A., Baranov, V. I., & Hedley, D. W. (2017) · Cytometry Part A · doi:10.1002/cyto.a.23053 · Cited by 300 · cited 1×
“155 Notably, IMC preserves the antigen speci fi city and can simultaneously provide the spatially resolved analysis of 32 proteins.”
BackgroundKhorrami, M., Prasanna, P., Gupta, A., Patil, P., Velu, P. D., Thawani, R., Corredor, G., Alilou, M., Bera, K., Fu, P., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0476 · Cited by 297 · cited 1×
“190 On the other hand, radiomics applications in immunotherapy start with a radiomics signature of CD8 + T cell output by a machine learning model.”
BackgroundA Map of Human Type 1 Diabetes Progression by Imaging Mass Cytometry
Damond, N., Engler, S., Zanotelli, V. R. T., Schapiro, D., Wasserfall, C. H., Kusmartseva, I., Nick, H. S., Thorel, F., Herrera, P. L., Atkinson, M. A., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.014 · Cited by 292 · cited 1×
“156 On this basis, Damond et al. 157 presented a new mechanism of type I diabetes progression as follows: the loss of β cell markers and recruitment of cytotoxic T cells and T helper cells precede β cell destruction.”
BackgroundGong, T., & Szustakowski, J. D. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt090 · Cited by 290
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes
Racle, J., Michaux, J., Rockinger, G. A., Arnaud, M., Bobisse, S., Chong, C., Guillaume, P., Coukos, G., Harari, A., Jandus, C., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0289-6 · Cited by 289 · cited 1×
“184 Racle et al. 103 developed a motif deconvolution algorithm, i.e., Modec, to train the deep learning MHC-II peptide predictor MixMHC2pred.”
MethodGeospatial immune variability illuminates differential evolution of lung adenocarcinoma
TRACERx Consortium, AbdulJabbar, K., Raza, S. E. A., Rosenthal, R., Jamal-Hanjani, M., Veeriah, S., Akarca, A., Lund, T., Moore, D. A., Salgado, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0900-x · Cited by 286 · cited 2×
“201 Furthermore, predictive models that incorporate the immune cell composition and spatial organization correlate with cancer prognosis, which several groups have proven in colorectal cancer, HCC, and melanoma 202 – 205 (Fig.”
BackgroundHLA‐HD: An accurate HLA typing algorithm for next‐generation sequencing data
Kawaguchi, S., Higasa, K., Shimizu, M., Yamada, R., & Matsuda, F. (2017) · Human Mutation · doi:10.1002/humu.23230 · Cited by 273
Butterfield, L. H. (2015) · BMJ · doi:10.1136/bmj.h988 · Cited by 272
HLA typing from RNA-Seq sequence reads
Boegel, S., Löwer, M., Schäfer, M., Bukur, T., de Graaf, J., Boisguérin, V., Türeci, Ö., Diken, M., Castle, J. C., & Sahin, U. (2012) · Genome Medicine · doi:10.1186/gm403 · Cited by 270 · cited 2×
“70,72 After a long development period, limited by their ef fi ciency and reliability, serological and cellular typing methods have been gradually replaced by DNA typing methods.”
BackgroundMethodComputational genomics tools for dissecting tumour–immune cell interactions
Hackl, H., Charoentong, P., Finotello, F., & Trajanoski, Z. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.67 · Cited by 270 · cited 3×
“50,51 55 – 57 Regarding liquid tumor analysis, Strelka2 introduces a normal sample contamination model to improve the variant calling accuracy and functions fairly well in the computing cost.”
BackgroundMethodDeconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq
(2020) · Methods in Enzymology · doi:10.1016/bs.mie.2019.05.056 · Cited by 269 · cited 1×
“31 Recently, more novel deconvolution-based algorithms have been developed.”
BackgroundTumor Microenvironment, Metabolism, and Immunotherapy
DeBerardinis, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmcibr1914890 · Cited by 266
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Single-cell-based technologies have enabled a better dissection of the TME through precise monitoring of cell sub-populations and spatial architecture, thus revealing the heterogeneous and complex nature of the TME [10, 12].”
BackgroundArtificial Intelligence in Dermatology Image Analysis: Current Developments and Future Trends
Li, Z., Koban, K. C., Schenck, T. L., Giunta, R. E., Li, Q., & Sun, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226826 · Cited by 248
Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
Zou, J., Wang, L., Tang, H., Liu, X., Peng, F., & Peng, C. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413335 · Cited by 150
“Bioinformatics is a novel analysis technology widely used for the prediction of outcomes in cancer immunotherapy [70].”
CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer
Selvakumar, S. C., Preethi, K. A., Ross, K., Tusubira, D., Khan, M. W. A., Mani, P., Rao, T. N., & Sekar, D. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01565-1 · Cited by 139
“As a result, NGS technology has become the foundation for developing targeted immunotherapy for cancer, as well as the development of individualized treatment plans for cancer patients [42].”
Zhang, Y., Xu, M., Ren, Y., Ba, Y., Liu, S., Zuo, A., Xu, H., Weng, S., Han, X., & Liu, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01980-6 · Cited by 133
“Imaging histology, as a non-invasive imaging method, has shown great potential in the diagnosis and treatment of tumours by combining learning models with digital pathology [125].”
Method
Metadata
- Authors
- Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Xiao, Yi
- Shao, Zhi-Ming
- Jiang, Yi-Zhou
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-08-20
- Volume
- 6
- Issue
- 1
- Pages
- 312-312
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8377461
- OpenAlex
- W3194492341
- Cited by
- 163
- References
- 303
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 38 · 2023: 50 · 2022: 16 · 2021: 5
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81874113, 82002792, 81922048, 81874112)
- Fok Ying Tong Education Foundation (171034)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- cancer immunotherapy, tumor immune microenvironment, immunogenomics, immunoproteomics, single-cell analysis, artificial intelligence, radiomics, digital pathology, deep learning, immune checkpoint blockade, immunotherapy response prediction, tumor heterogeneity, immune cell subpopulations
- MeSH terms
- Antigens, Neoplasm, Artificial Intelligence, Humans, Immunity, Innate, Immunogenetics, Immunotherapy, Neoplasms, Biomarkers, Tumor, Genome, Human, Cell Lineage, Proteome, Single-Cell Analysis, Tumor Microenvironment, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.